Walton Acquires 245-acre Lee Farms Property in Loveland, Colo.
Walton Global Holdings Ltd. and its affiliates (collectively Walton), a real estate investment and land asset company with US$3.8 billion under management and administration, has acquired the 245-acre Lee Farms property located at 4300 Wilson Ave. in Loveland, Colo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005268/en/
The 245-acre Lee Farms property in Loveland, Colo. is slated for a single-family residential master planned community of approximately 900 units. (Graphic: Business Wire)
The pre-developed land is slated for a single-family residential master planned community of approximately 900 units, offering a variety of sizes and types of homesites. The parcel is located within close proximity to existing and actively selling new-home communities of Meadowbrook Ridge, Mariana Butte and The Lakes at Centerra.
The property was acquired from The True Life Companies and the Lee Family.
Located 14 minutes from Fort Collins, Colo., home to Colorado State University, the Loveland region boasts a strong economy featuring dozens of innovative businesses from tech start-ups to Fortune 500 companies, low unemployment, and a steady population growth that is driving demand for residential construction.
Brett Limbaugh, Director of Development Services for the City of Loveland believes this is a good time to take advantage of the current market conditions stating, “We are excited to work with Walton on moving the Lee Farms development forward and seeing additional growth in the market area.”
Concurrent to the purchase of the Lee Farms property, Walton has secured interest from a top publicly-traded homebuilder with plans to begin development of the land in 2020. Negotiations are underway with an Exit Focused Letter of Intent that affords the builder a first right of refusal for a phased procurement of the property. It is anticipated the land will be developed in multiple phases, providing distributions to investors as the builder sells homes.
The Loveland, Colo. land acquisition adds to Walton’s 85,000-acre portfolio located across the United States, providing a scalable land acquisition platform to support homebuilders with just-in-time inventory management. Walton’s approach is an innovative response to secular shifts in the land development industry, which is increasingly challenged to finance acquisition with debt.
Walton recently announced its first Builder Option Land Development fund (the BOLD Fund), that provides homebuilders with a land acquisition opportunity to work alongside an international real estate investment and asset management company for securing a land pipeline with minor upfront capital contribution.
“The benefits of working with national builders through these Exit Focused Agreements by holding land for future development, is opening up tremendous opportunities for Walton in all markets where we research and acquire land,” said Barry Dluzen, Senior Vice President - Land of Walton Global Holdings.
For over 40 years, Walton has researched, planned, and structured pre-development land investments located in the major growth corridors throughout the U.S. and Canada. The evolution of Walton has opened the door to offering new products, like the BOLD Fund, creating new opportunities for investors and homebuilders.
About Walton Global Holdings
Walton Global Holdings is a privately owned, leading global real estate investment, land asset management and administration company that has focused on strategically located land in major growth corridors for over 40 years. The company manages and administers US$3.8 billion of real estate assets in North America, on behalf of its investors and business partners. Walton has more than 106,000 acres of land under ownership, management and administration in the United States and Canada. For more information visit Walton.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005268/en/
Contact information
MEDIA CONTACT:
Jennifer Whittle
LAVIDGE
480-998-2600
Jwhittle@lavidge.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KAYTUS Unveils Upgraded MotusAI to Accelerate LLM Deployment12.6.2025 14:11:00 EEST | Press release
KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, today announced the release of the latest version of its MotusAI AI DevOps Platform at ISC High Performance 2025. The upgraded MotusAI platform delivers significant enhancements in large model inference performance and offers broad compatibility with multiple open-source tools covering the full lifecycle of large models. Engineered for unified and dynamic resource scheduling, it dramatically improves resource utilization and operational efficiency in large-scale AI model development and deployment. This latest release of MotusAI is set to further accelerate AI adoption and fuel business innovation across key sectors such as education, finance, energy, automotive, and manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612546292/en/ MotusAI Dashboard As large AI models become increasingly embedded in real-world applications, enterprises are
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 14:00:00 EEST | Press release
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefi
Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 14:00:00 EEST | Press release
As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s coming next,” said Andrew Busch, economic futurist and economist at AndrewBusch.com. “Tariffs are no longer just a policy lever; they’re a strategic force reshaping the g
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce the company’s strategic vision to redefine the standard of care for B-cell malignancies. “The data presented at EHA 2025 underscore the strength of BeOne’s comprehensive hematology pipeline, built on the success of BRUKINSA, the only BTK inhibitor to demonstrate superior progression-free survival over ibrutinib in a Phase 3 trial,1” said Lai Wang, Ph.D. Global Head of R&D at BeOne. “With our potentially best-in-class BCL2 inhibitor, sonrotoclax, and fi
Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 11:17:00 EEST | Press release
Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involvement in the IPCEI-CIS project, along with partnerships with Deutsche Telekom AG, NVIDIA, Telefónica, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom